Immunology Investor Event

sanofi Pivotal results support Dupixent'sⓇ potential as the first and only biologic for Eosinophilic Esophagitis U.S. regulatory submission completed, pending FDA acceptance Proportion of patients achieving peak esophageal eosinophil count ≤ 6 eos/hpf FDA Breakthrough Therapy Designation Absolute change from baseline in DSQ score, symptoms Responders (%) 80 88 100 60 60 40 Part A P < 0.0001 *** 60% 20 5% 6% 0 Placebo dupilumab 300 mg qw Placebo Part B P < 0.0001 *** 59% dupilumab 300 mg qw Absolute change from baseline, LS mean (SE) Part A Placebo dupilumab 300 mg qw Placebo 0 -15 15212 -5 -10 -9.6 -20 -25 -30 -21.9 I *** P < 0.001 I -13.9 Part B dupilumab 300 mg qw *** P < 0.0001 -23.8 Sources: Rothenberg Met al., Journal of Allergy and Clinical Immunology, Vol 149, Issue 2, Supplement, 2022, Pg AB312, The safety results of the trials were generally consistent with the known safety profile of Dupixent in its approved indications. For the 24-week treatment period, overall rates of adverse events were 84% (67/80) for Dupixent 300 mg weekly and 71% (55/78) for placebo. Dupixent in EoE is investigational and has not been fully reviewed by regulatory authorities; Dupixent is developed and commercialized in collaboration with Regeneron 23 Immunology Investor Event

View entire presentation